16th October 2017
Having worked on the original IPO of Levrett, Shakespeare Martineau advised on all aspects of Nuformix’s reverse takeover and placing, as well as the relisting on the Standard List and the London Stock Exchange. Keith Spedding, corporate partner at Shakespeare Martineau, said: “The deal is a testament to the impressive IP assets held by Nuformix and the potential for these methods to produce lifesaving treatments.”
Link to the article here